Citigroup
SGMO

Citigroup’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Citigroup’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$245K – 5935
2022
Q3 		$245K Buy
50,000
+18,200
+57% +$93.5K ﹤0.01% 3688
2022
Q2 		$132K Buy
+31,800
New +$138K ﹤0.01% 4065
2021
Q1 		– Sell
-164,800
Closed -$2.57M – 7239
2020
Q4 		$2.57M Buy
164,800
+121,400
+280% +$1.42M ﹤0.01% 2612
2020
Q3 		$410K Sell
43,400
-5,200
-11% -$56.2K ﹤0.01% 4026
2020
Q2 		$435K Sell
48,600
-6,900
-12% -$64K ﹤0.01% 4388
2020
Q1 		$354K Buy
55,500
+2,500
+5% +$18.6K ﹤0.01% 4201
2019
Q4 		$444K Sell
53,000
-9,100
-15% -$83.7K ﹤0.01% 4522
2019
Q3 		$562K Sell
62,100
-3,800
-6% -$42.6K ﹤0.01% 4232
2019
Q2 		$710K Sell
65,900
-28,400
-30% -$302K ﹤0.01% 4051
2019
Q1 		$900K Sell
94,300
-36,000
-28% -$368K ﹤0.01% 3524
2018
Q4 		$1.5M Buy
130,300
+26,300
+25% +$327K ﹤0.01% 2964
2018
Q3 		$1.76M Buy
104,000
+28,000
+37% +$426K ﹤0.01% 2877
2018
Q2 		$1.08M Buy
76,000
+2,900
+4% +$48.2K ﹤0.01% 3281
2018
Q1 		$1.39M Sell
73,100
-29,100
-28% -$622K ﹤0.01% 2937
2017
Q4 		$1.68M Buy
102,200
+56,500
+124% +$841K ﹤0.01% 2850
2017
Q3 		$686K Buy
45,700
+24,200
+113% +$268K ﹤0.01% 3779
2017
Q2 		$189K Buy
21,500
+13,700
+176% +$87.9K ﹤0.01% 4846
2017
Q1 		$41K Sell
7,800
-13,300
-63% -$53.4K ﹤0.01% 5840
2016
Q4 		$64K Buy
21,100
+12,100
+134% +$44.1K ﹤0.01% 6028
2016
Q3 		$42K Buy
9,000
+6,900
+329% +$35.1K ﹤0.01% 5785
2016
Q2 		$12K Sell
2,100
-7,200
-77% -$45.9K ﹤0.01% 6456
2016
Q1 		$56K Buy
9,300
+3,800
+69% +$22.8K ﹤0.01% 6049
2015
Q4 		$50K Sell
5,500
-500
-8% -$3.85K ﹤0.01% 5941
2015
Q3 		$34K Buy
6,000
+3,400
+131% +$28K ﹤0.01% 5685
2015
Q2 		$29K Buy
+2,600
New +$33.5K ﹤0.01% 5893

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citigroup's SGMO Position: Q4 2025 in Review

Citigroup sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 1,369 shares — an estimated $922 sold.

Citigroup first reported a position in SGMO in Q2 2013 and held it in 50 quarters. The position peaked at $5.47M in Q1 2021. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Citigroup reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 1,369 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $922.
  • Citigroup first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 50 quarters.
  • Citigroup's SANGAMO THERAPEUTICS INC position peaked at $5.47M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.